Human TNFRSF11B ELISA Kit

Alternative name
Human osteoclastogenesis inhibitory factor ELISA Kit;Human osteoprotegerin ELISA Kit;Human OCIF ELISA Kit;Human OPG ELISA Kit;Human PDB5 ELISA Kit;Human TR1 ELISA Kit;Human TNF receptor superfamily member 11b ELISA Kit;Human tumor necrosis factor receptor superfamily member 11B ELISA Kit;Human tumor necrosis factor receptor superfamily, member 11b ELISA Kit;
Catalog
E027709
species
Human
GeneTNFRSF11B
SpecificityNatural and recombinant human OPG
SamplesSerum, Plasma , tissue homogenates,Cell culture supernates,Other biological fluids.
Sensitivity< 5pg/ml
Intended UseHuman TNFRSF11B ELISA Kit allows for the in vitro quantitative determination of TNFRSF11B , concentrations in serum, Plasma , tissue homogenates and Cell culture supernates and Other biological fluids.
StorageStore the whole ELISA kit at 4℃
Product Description
specificalPrinciple of the assay: human OPG ELISA Kit was based on standard sandwich enzyme-linked immune-sorbent assay technology. A monoclonal antibody from mouse specific for OPG has been precoated onto 96-well plates. Standards (NSO,E22-L401) and test samples are added to the wells, a biotinylated detection polyclonal antibody from goat specific for OPG is added subsequently and then followed by washing with PBS or TBS buffer. Avidin-Biotin-Peroxidase Complex was added and unbound conjugates were washed away with PBS or TBS buffer. HRP substrate TMB was used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the human OPG amount of sample captured in plate. Background: Osteoprotegerin (OPG) is identical to osteoclastogenesis inhibitory factor (OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis.1 OPG is considered to play an important rolein the regulation of bone resorption by modifying osteoclast differentiation.2 Osteoprotegerin is an independent riskfactor for the progression of atherosclerosis and onset of cardiovascular disease.3 It can act as a soluble factor inthe regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity.4 OPG system may play a critical role in the development of osteolytic bone disease in multiplemyeloma and that targeting this system may have therapeutic potential.5 OPG also plays a role in the vascularsystem.6 The standard product used in this kit is recombinant OPG, a 55KDa glycoprotein.
Human Tumor necrosis factor receptor superfamily member 11B Protein information
Uniprot ID TR11B_HUMAN
Uniprot AC O00300; B2R9A8; O60236; Q53FX6; Q9UHP4;
UniGene Hs.81791;
GeneID 4982
KEGG hsa:4982;
Human Tumor necrosis factor receptor superfamily member 11B Protein SEQUENCE
SEQUENCE 401 AA; 46026 MW; 2A23AC07BFA1E2DE CRC64;
MNNLLCCALV FLDISIKWTT QETFPPKYLH YDEETSHQLL CDKCPPGTYL
KQHCTAKWKT VCAPCPDHYY TDSWHTSDEC LYCSPVCKEL QYVKQECNRT
HNRVCECKEG RYLEIEFCLK HRSCPPGFGV VQAGTPERNT VCKRCPDGFF
SNETSSKAPC RKHTNCSVFG LLLTQKGNAT HDNICSGNSE STQKCGIDVT
LCEEAFFRFA VPTKFTPNWL SVLVDNLPGT KVNAESVERI KRQHSSQEQT
FQLLKLWKHQ NKDQDIVKKI IQDIDLCENS VQRHIGHANL TFEQLRSLME
SLPGKKVGAE DIEKTIKACK PSDQILKLLS LWRIKNGDQD TLKGLMHALK
HSKTYHFPKT VTQSLKKTIR FLHSFTMYKL YQKLFLEMIG NQVQSVKISC
L
UCSC uc003yon.5; human.;

Category

Human TNFRSF11B ELISA Kit